<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pediatr Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">J Pediatr Genet</journal-id>
<journal-id journal-id-type="doi">10.1055/s-00029027</journal-id>
<journal-title-group>
<journal-title>Journal of Pediatric Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">2146-4596</issn>
<issn pub-type="epub">2146-460X</issn>
<publisher>
<publisher-name>Georg Thieme Verlag KG</publisher-name>
<publisher-loc>Stuttgart · New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27617127</article-id>
<article-id pub-id-type="pmc">4918721</article-id>
<article-id pub-id-type="doi">10.1055/s-0035-1564443</article-id>
<article-id pub-id-type="publisher-id">1506</article-id>
<article-categories>
<subj-group>
<subject>Review Article</subject>
</subj-group>
<series-title>Genetic Advances in Intellectual Disability</series-title>
<series-text>Guest Editor: Donatella Milani, MD</series-text>
</article-categories>
<title-group>
<article-title>Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith–Magenis and Potocki–Lupski Syndromes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Neira-Fresneda</surname>
<given-names>Juanita</given-names>
</name>
<xref ref-type="aff" rid="AF1506-1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Potocki</surname>
<given-names>Lorraine</given-names>
</name>
<xref ref-type="aff" rid="AF1506-1">1</xref>
<xref ref-type="aff" rid="AF1506-2">2</xref>
<xref ref-type="author-notes" rid="CO1506-1"></xref>
</contrib>
</contrib-group>
<aff id="AF1506-1">
<label>1</label>
<institution>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States</institution>
</aff>
<aff id="AF1506-2">
<label>2</label>
<institution>Texas Children's Hospital, Houston, Texas, United States</institution>
</aff>
<author-notes>
<corresp id="CO1506-1"><bold>Address for correspondence </bold>Lorraine Potocki, MD, FACMG <institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution><addr-line>Texas Children's Hospital, 6701 Fannin Street, Suite 1560</addr-line><addr-line>Houston, TX 77030</addr-line><email>lpotocki@bcm.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2015</year>
</pub-date>
<volume>4</volume>
<issue>3</issue>
<fpage>159</fpage>
<lpage>167</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>6</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© Thieme Medical Publishers</copyright-statement>
</permissions>
<abstract>
<p>Smith–Magenis syndrome (SMS) and Potocki–Lupski syndrome (PTLS) are reciprocal contiguous gene syndromes within the well-characterized 17p11.2 region. Approximately 3.6 Mb microduplication of 17p11.2, known as PTLS, represents the mechanistically predicted homologous recombination reciprocal of the SMS microdeletion, both resulting in multiple congenital anomalies. Mouse model studies have revealed that the retinoic acid–inducible 1 gene (<italic>RAI1</italic>) within the SMS and PTLS critical genomic interval is the dosage-sensitive gene responsible for the major phenotypic features in these disorders. Even though PTLS and SMS share the same genomic region, clinical manifestations and behavioral issues are distinct and in fact some mirror traits may be on opposite ends of a given phenotypic spectrum. We describe the neurobehavioral phenotypes of SMS and PTLS patients during different life phases as well as clinical guidelines for diagnosis and a multidisciplinary approach once diagnosis is confirmed by array comparative genomic hybridization or <italic>RAI1</italic> gene sequencing. The main goal is to increase awareness of these rare disorders because an earlier diagnosis will lead to more timely developmental intervention and medical management which will improve clinical outcome.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>congenital heart disease</kwd>
<kwd>autism</kwd>
<kwd>intellectual disability</kwd>
<kwd>mirror traits</kwd>
<kwd>gene dosage</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>